Cannabis Bioscience International Holdings Inc Financials
Financial Health Signals
Cannabis Bioscience International Holdings Inc passes 4 of 9 financial strength tests. 1 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, both operating efficiency signals pass.
For every $1 of reported earnings, Cannabis Bioscience International Holdings Inc generates $0.60 in operating cash flow (-$330K OCF vs -$549K net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Cannabis Bioscience International Holdings Inc earns $-3.1 in operating income for every $1 of interest expense (-$421K vs $136K). This narrow margin raises concern about the company's ability to service its debt if operating income declines.
This page shows Cannabis Bioscience International Holdings Inc (CBIH) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 3 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Key Financial Metrics
Cannabis Bioscience International Holdings Inc generated $303K in revenue in fiscal year 2025. This represents an increase of 21.8% from the prior year.
Cannabis Bioscience International Holdings Inc reported -$549K in net income in fiscal year 2025. This represents an increase of 15.7% from the prior year.
Cannabis Bioscience International Holdings Inc earned $-0.00 per diluted share (EPS) in fiscal year 2025. This represents an increase of 0.0% from the prior year.
Cannabis Bioscience International Holdings Inc held $13K in cash against $250K in long-term debt as of fiscal year 2025.
Cannabis Bioscience International Holdings Inc had 11.63B shares outstanding in fiscal year 2025. This represents an increase of 11.5% from the prior year.
Cannabis Bioscience International Holdings Inc's gross margin was 86.8% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is up 5.1 percentage points from the prior year.
Cannabis Bioscience International Holdings Inc's operating margin was -139.1% in fiscal year 2025, reflecting core business profitability. This is up 56.3 percentage points from the prior year.
Cannabis Bioscience International Holdings Inc's net profit margin was -181.1% in fiscal year 2025, showing the share of revenue converted to profit. This is up 80.6 percentage points from the prior year.
CBIH Income Statement
| Metric | Q1'25 | Q3'25 | Q3'24 | Q1'24 | Q2'24 | Q2'23 | Q1'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $24K+62.1% | $15K-59.0% | $36K-79.6% | $179K | N/A | $64K-12.5% | $73K+42.1% | $51K |
| Cost of Revenue | $8K-58.0% | $19K+64.2% | $12K+41.2% | $8K | N/A | $15K+71.1% | $9K-63.4% | $24K |
| Gross Profit | $16K+459.6% | -$4K-118.1% | $25K-85.6% | $171K | N/A | $49K-24.0% | $64K+135.9% | $27K |
| R&D Expenses | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| SG&A Expenses | $23K-53.5% | $50K+98.4% | $25K-58.7% | $61K | N/A | $8K-82.5% | $48K-0.9% | $48K |
| Operating Income | -$75K+42.1% | -$129K+19.2% | -$160K-63.9% | -$98K | N/A | -$95K+46.5% | -$177K+37.9% | -$285K |
| Interest Expense | $17K-22.7% | $22K-54.3% | $49K+2004.4% | $2K | N/A | $30K+497.7% | $5K-87.4% | $40K |
| Income Tax | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income | -$83K+54.4% | -$181K-127.9% | -$80K-4.2% | -$76K | N/A | -$124K+31.6% | -$182K+44.0% | -$325K |
| EPS (Diluted) | $0.00 | $0.00 | $0.00 | $0.00 | N/A | $0.00 | $0.00 | $0.00 |
CBIH Balance Sheet
| Metric | Q1'25 | Q3'25 | Q3'24 | Q1'24 | Q2'24 | Q2'23 | Q1'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $19K+27.2% | $15K-84.2% | $94K+103.1% | $46K-19.0% | $57K-43.9% | $102K | N/A | N/A |
| Current Assets | $19K+400.3% | $4K-79.5% | $18K-1.7% | $19K-12.8% | $21K+8.9% | $20K | N/A | N/A |
| Cash & Equivalents | $223-59.3% | $548-31.0% | $794-18.1% | $969+28.3% | $755+124.0% | $337-92.9% | $5K-81.5% | $26K |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | $9K+239.6% | $3K-84.5% | $17K-0.8% | $17K-14.7% | $20K+3.8% | $19K | N/A | N/A |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $1.3M+2.0% | $1.2M+15.9% | $1.1M-2.9% | $1.1M-3.0% | $1.1M+20.4% | $944K | N/A | N/A |
| Current Liabilities | $1.0M+4.7% | $970K+21.1% | $801K-6.0% | $852K-3.4% | $882K+33.6% | $660K | N/A | N/A |
| Long-Term Debt | $250K0.0% | $250K0.0% | $250K0.0% | $250K+0.1% | $249K-0.1% | $250K | N/A | N/A |
| Total Equity | -$1.2M-1.7% | -$1.2M-5.2% | -$1.2M-10.4% | -$1.1M+2.2% | -$1.1M-28.2% | -$842K-17.3% | -$717K-49.0% | -$482K |
| Retained Earnings | -$6.0M-5.2% | -$5.7M-9.1% | -$5.2M+3.9% | -$5.4M-1.4% | -$5.3M-2.6% | -$5.2M | N/A | N/A |
CBIH Cash Flow Statement
| Metric | Q1'25 | Q3'25 | Q3'24 | Q1'24 | Q2'24 | Q2'23 | Q1'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$104K | N/A | -$9K+70.2% | -$30K+82.6% | -$174K+21.2% | -$221K-196.5% | -$75K+62.9% | -$201K |
| Capital Expenditures | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Investing Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Financing Cash Flow | $157K | N/A | $10K-68.9% | $31K-82.4% | $174K-19.6% | $217K+207.8% | $70K-65.3% | $203K |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
CBIH Financial Ratios
| Metric | Q1'25 | Q3'25 | Q3'24 | Q1'24 | Q2'24 | Q2'23 | Q1'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 66.3%+96.2pp | -29.9%-97.5pp | 67.6%-27.8pp | 95.3% | N/A | 76.3%-11.6pp | 87.9%+35.0pp | 52.9% |
| Operating Margin | -309.0%+556.5pp | -865.5%-426.2pp | -439.4%-384.8pp | -54.6% | N/A | -148.3%+94.5pp | -242.8%+313.0pp | -555.8% |
| Net Margin | -341.5%+872.4pp | -1213.9%-639.3pp | -574.5%-531.9pp | -42.7% | N/A | -195.2%+54.5pp | -249.6%+383.8pp | -633.5% |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | -436.3%+781.2pp | -1217.5%-994.9pp | -222.6%-57.7pp | -164.9% | N/A | -122.2% | N/A | N/A |
| Current Ratio | 0.02+0.0 | 0.00-0.0 | 0.020.0 | 0.020.0 | 0.020.0 | 0.03 | N/A | N/A |
| Debt-to-Equity | -0.200.0 | -0.20+0.1 | -0.26-0.0 | -0.240.0 | -0.23+0.1 | -0.30 | N/A | N/A |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Note: Shareholder equity is negative (-$1.2M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Note: The current ratio is below 1.0 (0.03), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Frequently Asked Questions
What is Cannabis Bioscience International Holdings Inc's annual revenue?
Cannabis Bioscience International Holdings Inc (CBIH) reported $303K in total revenue for fiscal year 2025. This represents a 21.8% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Cannabis Bioscience International Holdings Inc's revenue growing?
Cannabis Bioscience International Holdings Inc (CBIH) revenue grew by 21.8% year-over-year, from $249K to $303K in fiscal year 2025.
Is Cannabis Bioscience International Holdings Inc profitable?
No, Cannabis Bioscience International Holdings Inc (CBIH) reported a net income of -$549K in fiscal year 2025, with a net profit margin of -181.1%.
What is Cannabis Bioscience International Holdings Inc's earnings per share (EPS)?
Cannabis Bioscience International Holdings Inc (CBIH) reported diluted earnings per share of $-0.00 for fiscal year 2025. This represents a 0.0% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.
How much debt does Cannabis Bioscience International Holdings Inc have?
As of fiscal year 2025, Cannabis Bioscience International Holdings Inc (CBIH) had $13K in cash and equivalents against $250K in long-term debt.
What is Cannabis Bioscience International Holdings Inc's gross margin?
Cannabis Bioscience International Holdings Inc (CBIH) had a gross margin of 86.8% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is Cannabis Bioscience International Holdings Inc's operating margin?
Cannabis Bioscience International Holdings Inc (CBIH) had an operating margin of -139.1% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Cannabis Bioscience International Holdings Inc's net profit margin?
Cannabis Bioscience International Holdings Inc (CBIH) had a net profit margin of -181.1% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Cannabis Bioscience International Holdings Inc's operating cash flow?
Cannabis Bioscience International Holdings Inc (CBIH) generated -$330K in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Cannabis Bioscience International Holdings Inc's total assets?
Cannabis Bioscience International Holdings Inc (CBIH) had $32K in total assets as of fiscal year 2025, including both current and long-term assets.
How many shares does Cannabis Bioscience International Holdings Inc have outstanding?
Cannabis Bioscience International Holdings Inc (CBIH) had 11.63B shares outstanding as of fiscal year 2025.
What is Cannabis Bioscience International Holdings Inc's current ratio?
Cannabis Bioscience International Holdings Inc (CBIH) had a current ratio of 0.03 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.
What is Cannabis Bioscience International Holdings Inc's debt-to-equity ratio?
Cannabis Bioscience International Holdings Inc (CBIH) had a debt-to-equity ratio of -0.21 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Cannabis Bioscience International Holdings Inc's return on assets (ROA)?
Cannabis Bioscience International Holdings Inc (CBIH) had a return on assets of -1721.5% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Cannabis Bioscience International Holdings Inc's cash runway?
Based on fiscal year 2025 data, Cannabis Bioscience International Holdings Inc (CBIH) had $13K in cash against an annual operating cash burn of $330K. This gives an estimated cash runway of approximately 0 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
Why is Cannabis Bioscience International Holdings Inc's debt-to-equity ratio negative or unusual?
Cannabis Bioscience International Holdings Inc (CBIH) has negative shareholder equity of -$1.2M as of fiscal year 2025, which causes the debt-to-equity ratio to appear negative or not meaningful. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
What is Cannabis Bioscience International Holdings Inc's Piotroski F-Score?
Cannabis Bioscience International Holdings Inc (CBIH) has a Piotroski F-Score of 4 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Cannabis Bioscience International Holdings Inc's earnings high quality?
Cannabis Bioscience International Holdings Inc (CBIH) has an earnings quality ratio of 0.60x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Cannabis Bioscience International Holdings Inc cover its interest payments?
Cannabis Bioscience International Holdings Inc (CBIH) has an interest coverage ratio of -3.1x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.